65,437 trials
HIV · Vascular Diseases · Cardiovascular Diseases
Primary: Flow-mediated Dilation of the Brachial Artery — 2.25; 3.36 percent dilation of the brachial artery — p=0.52
Hearing Loss
Primary: Standard Hearing Test — 422; 107; 24; 4 participants
Influenza
Primary: Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) — 8…
Idiopathic Macular Hole
Primary: Visual Acuity (ETDRS Letters) — 74.9; 72.4; 72.2 Visual acuity in letters
Dilated Cardiomyopathy
Primary: Improvement in Left Ventricular Ejection Fraction — 42.1; 37.6 Percentage — p=0.267
HIV Infections
Primary: HIV Infection — 33; 35 participants
Allergic Rhinitis
Primary: Minimum Cross-Sectional Area (Amin) Proportion Measured Using Acoustic Rhinometry — 0.760; 0.742; 0.717; 0.795 ratio — p=0.302
Jaw, Edentulous, Partially
Primary: Marginal Bone Level Changes — -0.25; -0.50 millimeter
Hypertrichosis
Primary: Efficacy of Bimatoprost in Lengthening of Eyelashes — 2; 1.1 mm
Chronic Obstructive Pulmonary Disease
Primary: Maximal Response of Incremental Once Daily and Twice Daily Doses of NVA237 That Each Dose Achieves in Relation to the Maximal Effect of NVA237 on Trough Forced…
Smoking Cessation
Primary: Percentage of Self-reported Abstinence at 6 Weeks. — 12.3; 12.9 percentage of participants — p=0.74
Pancreatic Cancer
Primary: Two-year Disease Free Survival. — 26.1 percentage of patients
Partial Epilepsy
Primary: Seizure Frequency Over the 12-week Maintenance Period. — 7.88; 6.54; 6.00 Nº Standardized Seizures by 4 weeks — p=0.058
MPS IV A
Primary: Change From Baseline in Endurance as Measured by the 6-minute Walk Test — 211.9; 205.7; 203.9; 225.4 meters — p=0.0174
Diabetes Mellitus, Type 2 · Acute Coronary Syndrome
Primary: Percentage of Participants With Primary Major Adverse Cardiac Events (MACE) — 11.8; 11.3 percentage of participants — p=0.315